Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 115

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 115
---
 Agreement).

| 57 |

At any time from and after
the Commencement Date, on any business day that is also the VWAP Purchase Date for a VWAP Purchase, we may also direct the Selling Shareholder,
by delivery of an Additional VWAP Purchase Notice, to purchase, on the same business day, an additional number of Depositary Shares at
a purchase price equal to the lesser of 95% of (i) the closing price of a Depositary Share on the trading day immediately preceding the applicable Additional VWAP Purchase Date and (ii) the VWAP during the Additional VWAP Purchase Period (as defined in the Purchase Agreement) on the applicable Additional VWAP Purchase Date.

Notwithstanding the above,
in no event may the aggregate amount of Purchase Shares submitted in any single or combination of VWAP Purchase Notices and/or Additional
VWAP Purchase Notices on a particular date require a payment from the Selling Shareholder to us that exceeds $2,500,000, unless such limitation
is waived by the Selling Shareholder.

For purposes of the Purchase
Agreement, “VWAP” shall mean the daily volume weighted average price of the Depositary Shares on Nasdaq as reported by Bloomberg
through its “AQR” function.

All such determinations shall
be appropriately adjusted for any sales of Depositary Shares through block transactions, any reorganization, non-cash dividend, stock
split, reverse share split, stock combination, recapitalization, Depositary Share-Ordinary Share ratio change or other similar transaction
during such period.

Commitment Fee, Commitment Shares and Other Fees

As consideration for its irrevocable
commitment to purchase our Depositary Shares under the Purchase Agreement, we have agreed to pay to the Selling Shareholder the Commitment
Fee as consideration for the Selling Shareholder entering into the Purchase Agreement. In the event that we fail to pay the Commitment
Fee when due, we shall have the right, at our discretion, to issue Depositary Shares representing the value of the Commitment Fee in aggregate,
valued at the closing sale price for the Depositary Shares on Nasdaq on the trading day immediately prior to the date of execution of
the Purchase Agreement, to release us of our liability to pay the Commitment Fee as a liquidated sum. To the extent Commitment Shares
are issued in lieu of paying the Commitment Fee, we intend to issue up to 612,500 Depositary Shares (equal to 1.75% of the Commitment